Dose-Evaluation Study of the Efficacy and Safety of TLA Gut™ Leukapheresis Treatment in Patients With Ulcerative Colitis

Not Applicable

Recruiting

• Conditions: Ulcerative Colitis (UC)
• Interventions: Device: TLA Gut™

• Registration Number: NCT04550130
• Lead Sponsor: TLA, Targeted Immunotherapies AB

Brief Summary

An open-label, randomised, multi-centre, dose evaluation study of the efficacy and safety of TLA Gut™ leukapheresis treatment in patients with UC. The aim of this trial is to evaluate the efficacy and safety of two different TLA Gut™ dose regimens in patients with acute exacerbation of UC. Enrolled patients will participate in a 6-week treatment phase and a 20- week follow-up phase. The treatment phase consists of two periods; 2 weeks in which patients will undergo two treatment sessions per week, followed by 4 weeks of a single treatment session per week. The follow-up phase consists of 2 visits, one visit at week 7 and the last visit at week 26. Telephone visits will be conducted between these visits. In all a patient will undergo 8 treatment visits and 2 follow-up visits. Only patients not having experienced an earlier recurrence will participate in the follow-up phase.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-04-09
• Study First Submitted QC: 2020-09-14
• Study First Posted: 2020-09-16
• Status Verified: 2022-11
• Last Update Submitted: 2022-11-07
• Last Update Posted: 2022-11-08
• Study Start: 2022-12
• Primary Completion: 2023-04
• Study Completion: 2023-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

Female or male patients 18 to 80 years of age

• Active UC without Ileorectal anastomosis (IRA)

• Active UC is defined as:

  • Total Mayo score of ≥ 6 to 11 points
  • Flexible rectosigmoidoscopy findings of 2 or 3 (0 inactive disease, 1; mild disease, 2; moderate disease or 3; severe disease)

• Minimum extension of inflammation 10 cm from anus.

• Active disease with no medical treatment OR Active disease despite receiving concomitant therapy with one or more of the following agents:

  • ≤20 mg prednisolone daily. Stable dose ≥1 week prior to the start of the investigation.
  • 5-Aminosalicylate (5-ASA) agents for ≥4 weeks and stable dose for ≥2 weeks (local or systemic administration)
  • Rectal administration of corticosteroids in a stable dose for ≥2 weeks
  • Azathioprine or 6-mercaptopurine for ≥8 weeks or stable dose ≥2 weeks

• No anti-tumour necrosis factor (TNF) treatment (Adalimumab, Infliximab, Golimumab, Certolizumab), anti-integrin-treatment (vedolizumab), Interleukin (IL)-12/23 inhibitor (Ustekinumab) or Janus Kinase (JAK) treatment (Tofacitinib) during the last 4 weeks prior to entering the study

• Patients with peripheral veins suitable for extracorporeal treatment - must be examined by the treating apheresis specialist

• Willing and able to give written informed consent

Exclusion Criteria

Involvement in any investigational drug or device trial within 30 days prior to this investigation

• Patients with peripheral veins not suitable for extracorporeal treatment
• Fever, defined as a temperature of >38,5 Celsius degrees (ºC), at the Screening Visit
• Heart failure
• Coronary artery disease
• Cardiomyopathy
• Valvular heart disease
• Cardiac arrythmia class IV
• Underweight person (BMI < 19)
• Hypotension (< 90/55 mmHG)
• Hypoproteinemia
• Evidence of toxic megacolon
• History of hypersensitivity to heparin
• Heparin-induced thrombocytopenia
• History of cerebrovascular incident
• Known clinically significant bleeding disorder
• Colectomy planned within 6 months
• Concomitant anticoagulant therapy
• History of hypercoagulable disorders
• Severe anaemia or Leukopenia
• Patients with active viral hepatitis and/or human immunodeficiency virus (HIV) infections
• A positive urine pregnancy test at the screening visit
• Patients that are nursing Local intestinal treatments with suppositories, enemas, creams, ointments or foams during the last 2 weeks
• Current daily smoking habits
• Patients unwilling to meet the requirements of the clinical investigational plan
• Other medical or social reasons for exclusion at the discretion of the investigator

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
low dose (1.8 L)	TLA Gut™	Patients in this arm will be treated with one column (Leukapheresis) and 1.8 L blood will be filtered.
high dose (3.6 L)	TLA Gut™	Patients in this arm will be treated with Two column (Leukapheresis) and 3.6 L blood will be filtered.

Primary Outcome Measures

Name	Time	Method
Evaluate whether the intervention of TLA Gut™ reduces Human Leukocyte Antigen DR isotype (HLADRhi)	baseline, during treatment (after 4 treatment sessions at week 2)	Mean percentage change in HLA-DRhi expressing monocytes

Secondary Outcome Measures

Name	Time	Method
Evaluate the effect of intervention of TLA Gut™ on clinical variables	baseline, after 4 treatment sessions at week 2 , immediately after treatment completion	Mean change and mean percentage change in Ulcerative Colitis Endoscopic Index of Severity (UCEIS) score
Evaluate the effect of intervention of TLA Gut™ on clinical, histopathology and laboratory criteria and variables	immediately after treatment completion	Proportion of patients in each dosing group achieving laboratory remission, clinical remission or both laboratory and clinical remission
Evaluate the effect of intervention of TLA Gut™ on laboratory criteria	baseline, during treatment (at week 6), immediately after treatment completion	Mean percentage change in faecal calprotectin levels

Trial Locations

Locations (1)

Ersta Sjukhus, Medicinkliniken; 🇸🇪 Stockholm, Sweden